Inflammatory acne management with a novel prescription dietary supplement

Journal of Drugs in Dermatology

Volumn 11, Issue 12, 2012, Pages 1428-1433

  Shalita, Alan R ^a   Falcon, Ronald ^b   Olansky, Alan ^c   Iannotta, Patricia ^d   Akhavan, Arash ^e   Day, Doris ^f   Janiga, Anthony ^g   Singri, Prashant ^h   Kallal, John E ⁱ  

^a Downstate Health Sciences University   (United States)

^b Long Beach Medical Center   (United States)

^c EMORY UNIVERSITY HOSPITAL   (United States)

^d ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g Advanced Clinical and Surgical Dermatology   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ Elorac Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; COPPER; FOLIC ACID; NICOTINAMIDE; PYRIDOXINE; ZINC;

ABSENCE OF SIDE EFFECTS; ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CHILD; DERMATOLOGIST; DIET SUPPLEMENTATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PATIENT SATISFACTION; PRESCRIPTION; PROSPECTIVE STUDY; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TABLET; TREATMENT DURATION;

ACNE VULGARIS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; COPPER; DICARBOXYLIC ACIDS; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NIACINAMIDE; PATIENT SATISFACTION; PRESCRIPTION DRUGS; PROSPECTIVE STUDIES; PYRIDOXINE; TETRACYCLINES; TREATMENT OUTCOME; YOUNG ADULT; ZINC;

EID: 84871064375     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Thiboutot A, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(5 suppl):S1-S50.
2. Cohen BA. Acne case studies. JHASIM Proceedings. 2008;8(2):36-39.
3. Bek-Thomsen M, Lomholt HB, Kilian M. Acne is not associated with yet-uncultured bacteria. J Clin Microbiol. 2008;46(10):3355-3360.
4. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379(9813):361-372.
5. Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58(1):56-59. (Pubitemid 350298137)
6. Fleischer AB Jr. Inflammation in rosacea and acne: Implications for patient care. J Drugs Dermatol. 2011;10(6):614-620.
7. Gannon M, Underhill M, Wellik K. Clinical inquiries.Which oral antibiotics are best for acne? J Fam Pract. 2011;60(5):290-292.
8. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004;292(6):726-735. (Pubitemid 39062528)
9. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56(4):651-663. (Pubitemid 46400177)
10. Koren G, Avner M, Shear N. Generic isotretinoin: a new risk for unborn children. CMAJ. 2004;170(10):1567-1568. (Pubitemid 38686189)
11. Dorschner RA, Pestonjamasp VK, Tamakuwala S, et al. Cutaneous injury This document contains proprietary information, images induces the release of cathelicidin anti-microbial peptides active against group A streptococcus. J Invest Dermatol. 2001;117(1):91-97. (Pubitemid 32652444)
12. Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55(2):77-81.
13. Hanifin JM, Tofte SJ. Update on therapy of atopic dermatitis. J Allergy Clin Immunol. 1999;104(3 pPt 2):S123-S125.
14. Shimoyama M, Kawai M, Hoshi Y, Ueda I. Nicotinamide inhibition of 3′,5′-cyclic AMP phosphodiesterase in vitro. Biochem Biophys Res Commun. 1972;49(4):1137-1141.
15. Stratford MR, Rojas A, Hall DW, et al. Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. Radiother Oncol. 1992;25(1):37-42.
16. Matts PJ, Oblong JE, Bissett DL. A review of the range of effects of niacinamide in human skin. Int Fed Soc Cosmet Chem Mag. 2002;5:285-289.
17. Fivenson DP. The mechanisms of action of nicotinamide and zinc in inflammatory skin disease. Cutis. 2006;77(1 suppl):5-10.
18. Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: a review. Diabetologia. 2000;43(11):1337-1345.
19. Niren NM, Torok HM. The Nicomide Improvement in Clinical Outcomes Study (NICOS): results of an 8-week trial. Cutis. 2006;77(1 suppl):17-28. (Pubitemid 43189145)
20. Wyczólkowska J, Maśliński C. Inhibition by nicotinamide of antigen-induced histamine release from mouse peritoneal mast cells. Int Arch Allergy Appl Immunol. 1976;50(6):729-736.
21. Draelos ZD. Clinical situations conducive to proactive skin health and antiaging improvement. J Investig Dermatol Symp Proc. 2008;13(1):25-27. (Pubitemid 351450902)
22. Ungerstedt JS, Blömback M, Söderström T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003;131(1):48-52. (Pubitemid 36098821)
23. Niren NM. Pharmacologic doses of nicotinamide in the treatment of inflammatory skin conditions: a review. Cutis. 2006;77(1 suppl):11-16. (Pubitemid 43189144)
24. Kyme P, Thoennissen NH, Tseng CW, et al. C/EBPε mediates nicotinamide-enhanced clearance of Staphylococcus aureus in mice. J Clin Invest. 2012;122(9):3316-3329.
25. Passi S, Picardo M, De Luca C, Nazzaro-Porro M. Mechanism of azelaic acid action in acne [in Italian]. G Ital Dermatol Venereol. 1989;124(10):455-463.
26. Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res. 1991;283(3):162-166.